About Isconova
Isconova is a company based in Uppsala (Sweden) founded in 1999 was acquired by Novavax in June 2013. Isconova has raised $5.02 million across 1 funding round from investors including Novavax and InnovationsKapital. Isconova has completed 1 acquisition, including Nordic Vaccine. Isconova operates in a competitive market with competitors including Serum Institute of India, Vaxcyte, Freeline, Vir Biotechnology and Biological E, among others.
- Headquarter Uppsala, Sweden
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Isconova
Isconova has successfully raised a total of $5.02M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.02 million completed in June 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Isconova
Isconova has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Novavax and InnovationsKapital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
Locked | Locked | Locked |
Investor details for Isconova
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Isconova
Isconova has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Nordic Vaccine.
Investment portfolio details for Isconova
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Adjuvants and vaccine delivery systems were developed for needle-free administration.
|
Locked | Locked | 2001 | Locked |
Complete acquisition details for Isconova
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Isconova
Detailed financials for Isconova
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Isconova Comparisons
Peer comparison for Isconova
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Isconova
Isconova operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Serum Institute of India, Vaxcyte, Freeline, Vir Biotechnology and Biological E, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| Locked | Locked | Locked |
Gene therapy platform is developed for chronic disease treatments.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
|
| Locked | Locked | Locked |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| Locked | Locked | Locked |
AAV-based gene therapies for rare diseases are developed.
|
Detailed competitors of Isconova
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Isconova
Complete news archive for Isconova
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Isconova
Isconova was founded in 1999 and raised its 1st funding round 9 years after it was founded.
Isconova is headquartered in Uppsala, Sweden. It is registered at Uppsala, Uppsala County, Sweden.
Isconova is a funded company, having raised a total of $5.02M across 1 funding round to date.
Isconova was founded as a spin-off from SLU to further develop its ISCOM technology. The technology was invented by Professor Bror Morein. The company seeks to make it commercially available as a platform for vaccine development and improved off-the-shelf research adjuvants Isconova was a leading international vaccine adjuvant company. Isconova was developing vaccines together with partners in the human and veterinary markets. The first vaccine using Isconovas nano-particle Matrix technology, Equilis, Prequenza, was launched on the veterinary market in 2005. In the human market, a number of vaccines are under development with Isconovas third generation nano-particle, Matrix MTM. Isconovas partners included Crucell, Pfizer, Merck Co., The Jenner Institute, Genocea, and Evolva. In July 2013, the company was acquired by Novavax.
Isconova's top competitors include Vaxcyte, Serum Institute of India and Biological E.
Isconova has made 1 acquisition, including Nordic Vaccine.
Isconova has 2 investors. Key investors include Novavax, and InnovationsKapital.